Log In or Create Account
CROI
Conference on Bacteriophages
RWHAP Clinical Conference
Podcasts
Slides
Question of the Week
Donate
Contact
Advanced Search
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
HIV Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Resources for Fellows and Others New to the HIV Field
On-Demand Webinars for Fellows
IAS-USA Guidelines and Recommendations
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Discrimination and Harassment Policy
Governance
Suggestions and Recommendations from San Francisco Locals
FAQs
Menu
Meaghan Castledine, PhD
Meaghan Castledine, PhD
University of Exeter
Exeter, United Kingdom
CROI
Conference on Bacteriophages
RWHAP Clinical Conference
Podcasts
Slides
Question of the Week
Donate
Contact
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
HIV Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Resources for Fellows and Others New to the HIV Field
On-Demand Webinars for Fellows
IAS-USA Guidelines and Recommendations
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Discrimination and Harassment Policy
Governance
Suggestions and Recommendations from San Francisco Locals
FAQs
Practice Question of the Week
November 3, 2025: Management of Antiretroviral Therapy in a Woman With Low-Level Viremia
A 50-year-old woman with HIV (CD4+ count, 500 cells/µL; plasma HIV RNA level, 500,000 copies/mL; no resistance mutations shown with pretreatment genotype testing) and gastroesophageal reflux disease is treated with bictegravir/emtricitabine (FTC)/tenofovir alafenamide (TAF). At week 12, her plasma HIV RNA level declines to 100 copies/mL. Over the next 12 months, her plasma HIV RNA level fluctuates between 50 and 100 copies/mL. How should she be managed?
A. Add doravirine to her treatment regimen
B. Change her treatment regimen to darunavir/cobicistat/TAF/FTC because of concern for resistance
C. Evaluate the patient for drug-drug interactions
D. Perform a proviral resistance genotype test
Register for the Course
View Archived Questions
Leave Feedback
Subscribe
CLOSE
